title: Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia.
abstract: Recombinant activated factor VII (rFVIIa) is a major alternative for management of hemophiliac patients with inhibitors. Additionally, it has been used off-label for the treatment of massive life-threatening hemorrhage associated with various bleeding situations. Herein, we describe a 16-month-old boy with acute megakaryoblastic leukemia and severe intractable gastrointestinal bleeding controlled by rFVIIa. rFVIIa should be considered as a novel treatment alternative in severe bleeding conditions including leukemias that may have hemostatic defects and platelet dysfunction.
authors.affiliation: Department of Pediatric Hematology, Gulhane Military Medical Academy, Ankara, Turkey. ekurekci@gata.edu.tr
authors.forename: A Emin
authors.initials: AE
authors.lastname: Kurekci
authors.forename: A Avni
authors.initials: AA
authors.lastname: Atay
authors.forename: Vedat
authors.initials: V
authors.lastname: Okutan
authors.forename: S Tolga
authors.initials: ST
authors.lastname: Yavuz
authors.forename: Okan
authors.initials: O
authors.lastname: Ozcan
mesh_terms: D005167:Factor VII / Q000008:administration & dosage*; D015942:Factor VIIa; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007223:Infant; D007947:Leukemia, Megakaryoblastic, Acute / Q000150:complications / Q000188:drug therapy; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage*
chemical_list: D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa